Venture Visionary Partners’s AC Immune ACIU Stock Holding History

Venture Visionary Partners’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-410	Closed	-$1.48K	–	472
2022 Q2	$1.48K	Buy	+410	New	+$1.4K	﹤0.01%	1564

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Venture Visionary Partners's ACIU Position: Q3 2022 in Review

Venture Visionary Partners sold out of AC Immune (ACIU) in Q3 2022, closing a stake of 410 shares — an estimated $1.48K sold.

Venture Visionary Partners first reported a position in ACIU in Q2 2022 and held it in 1 quarter. The position peaked at $1.48K in Q2 2022. 34 funds tracked by Wall St. Rank hold ACIU as of Q3 2022.

Venture Visionary Partners reported no remaining AC Immune position as of Q3 2022 after selling out during the quarter.
Venture Visionary Partners sold 410 AC Immune shares in Q3 2022, an estimated $1.48K.
Venture Visionary Partners first reported a position in AC Immune in Q2 2022 and held it in 1 quarter.
Venture Visionary Partners's AC Immune position peaked at $1.48K in Q2 2022.
34 funds tracked by Wall St. Rank held AC Immune as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.